Q1 Earnings Forecast for BDRX Issued By Zacks Research

Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) – Research analysts at Zacks Research issued their Q1 2026 earnings per share estimates for shares of Biodexa Pharmaceuticals in a research note issued to investors on Monday, June 29th. Zacks Research analyst D. Bautz forecasts that the company will post earnings of $0.00 per share for the quarter. Zacks Research also issued estimates for Biodexa Pharmaceuticals’ Q2 2026 earnings at $0.00 EPS, Q3 2026 earnings at $0.00 EPS and Q4 2026 earnings at $0.00 EPS.

Several other analysts also recently weighed in on BDRX. Weiss Ratings upgraded Biodexa Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a research report on Thursday, June 18th. Wall Street Zen downgraded shares of Biodexa Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, March 30th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Biodexa Pharmaceuticals has an average rating of “Sell”.

Biodexa Pharmaceuticals Stock Performance

BDRX opened at $2.91 on Wednesday. The stock’s 50 day simple moving average is $3.36 and its 200 day simple moving average is $6.75. Biodexa Pharmaceuticals has a 1 year low of $2.45 and a 1 year high of $66.50.

Institutional Inflows and Outflows

A hedge fund recently bought a new position in Biodexa Pharmaceuticals stock. Armistice Capital LLC acquired a new position in Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 100,000 shares of the company’s stock, valued at approximately $227,000. Armistice Capital LLC owned 14.71% of Biodexa Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission. 17.51% of the stock is owned by hedge funds and other institutional investors.

Biodexa Pharmaceuticals Company Profile

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease.